10-K: Kodiak Sciences Reports 2024 Results, Highlights Progress in Retinal Disease Pipeline

Kodiak Sciences announces its 2024 financial results and provides updates on its clinical programs targeting retinal diseases, including tarcocimab, KSI-501, and KSI-101.

Summary

• Kodiak Sciences is a biopharmaceutical company focused on developing treatments for retinal diseases.
• The company's lead investigational medicine, tarcocimab tedromer, is in Phase 3 clinical trials for diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).
• Topline data for the GLOW2 study in DR is expected in 1Q 2026, and for the DAYBREAK study in wet AMD in 2Q 2026.
• If both studies are successful, Kodiak intends to file a single Biologics License Application (BLA) in 2026 for wet AMD, RVO, and DR.
• KSI-501, a bispecific antibody biopolymer conjugate, is also being evaluated in the Phase 3 DAYBREAK study for wet AMD.
• KSI-101, a bispecific protein targeting IL-6 and VEGF, is in a Phase 1b study (APEX) to evaluate its safety and tolerability in patients with diabetic macular edema (DME) and macular edema secondary to inflammation (MESI).
• Kodiak is also advancing its Antibody Biopolymer Conjugate Drug (ABCD) Platform for glaucoma and geographic atrophy.
• As of December 31, 2024, Kodiak had $168.1 million in cash and cash equivalents.
• The company aims to become a leading retinal development and commercialization franchise.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. Positive clinical trial results are tempered by financial concerns and trial setbacks. The company is making progress but faces significant challenges.

Positives

• GLOW1 study met its primary endpoint, showing a significant improvement in DRSS score with tarcocimab.
• BEACON study demonstrated matched efficacy with differentiated durability versus aflibercept in RVO patients.
• DAYLIGHT study met its primary endpoint, showing non-inferior visual acuity gains with monthly tarcocimab compared to aflibercept.
• KSI-501 and KSI-101 clinical material were successfully manufactured in the first quarter of 2024.
• GLOW2 completed enrollment, randomizing more than 250 patients.
• Ursus, the custom-built manufacturing suite, was commissioned as a cGMP facility and released its first commercial scale cGMP batch of tarcocimab in July 2023.

Negatives

• GLEAM and GLIMMER studies did not meet their primary efficacy endpoints in DME patients.
• An unexpected increase in cataract adverse events was reported in the tarcocimab arms of the GLEAM and GLIMMER studies.
• The company has incurred net losses in each period since its inception and anticipates continuing to do so.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.

Risks

• The company is in the clinical stage of drug development with a limited operating history and no products approved for commercial sale.
• The company's prospects are heavily dependent on tarcocimab, KSI-501, and KSI-101 product candidates.
• Clinical trials may fail to demonstrate substantial evidence of the durability, efficacy, and safety of the company's product candidates.
• The company faces significant competition in an environment of rapid technological and scientific change.
• The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• The company expects to rely on third parties to conduct many aspects of its clinical trials and some aspects of its research and preclinical testing.
• The company contracts with third parties for the manufacture of materials for its product candidates and preclinical studies and clinical trials and for commercialization of any product candidates that it may develop.
• If the company is unable to obtain and maintain patent protection for any product candidates it develops or for its ABC Platform, its competitors could develop and commercialize products or technology similar or identical to its.
• The company is highly dependent on its key personnel, and if it is not successful in attracting, motivating, and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.

Future Outlook

Kodiak anticipates announcing topline data for GLOW2 in 1Q 2026 and DAYBREAK in 2Q 2026, with plans to file a single BLA in 2026 if both are successful.

Management Comments

• Kodiak has the potential to achieve our ambition of becoming an important retinal development and commercialization franchise, but we recognize there are substantial risks to realizing this potential.

Industry Context

The current standard of care for DR, RVO, and wet AMD is intravitreal administration of anti-VEGF therapies, principally Avastin, Lucentis, and Eylea, with newer competitors like Vabysmo and Eylea HD also gaining market share.

Comparison to Industry Standards

• Competitors like Roche (Vabysmo) and Regeneron (Eylea HD) have established products in the retinal disease space.
• Vabysmo demonstrated non-inferiority in visual acuity gains to Eylea in wet AMD and DME, with extended dosing of up to once every 16 weeks for slightly less than half of patients in Phase 3 trials at the Year 1 primary endpoint.
• Eylea HD demonstrated non-inferior visual acuity gains to Eylea in Phase 3 studies in wet AMD and DME while dosing a majority of patients on an every 3 or 4 month interval compared to Eylea dosed every 8 weeks per its label.

Stakeholder Impact

• Shareholders face risks related to the company's financial condition and the success of its clinical trials.
• Employees are subject to a Code of Business Conduct and Ethics and insider trading policies.
• Patients may benefit from the development of new treatments for retinal diseases.
• Suppliers and manufacturers are relied upon for the production of materials for clinical trials and potential commercialization.

Next Steps

• Announce topline data for GLOW2 in 1Q 2026.
• Announce topline data for DAYBREAK in 2Q 2026.
• File a single Biologics License Application (BLA) in 2026 for tarcocimab in wet AMD, DR and RVO, if GLOW2 and DAYBREAK are successful.
• Present additional APEX data at an Investor R&D update in June 2025.
• Initiate pivotal program for KSI-101 in 2Q 2025.

Key Dates

Keywords

retinal diseases, tarcocimab, KSI-501, KSI-101, ABC Platform, clinical trials, biopharmaceutical, wet AMD, diabetic retinopathy, RVO, BLA, FDA, manufacturing, ophthalmology